Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-PC: Trabedersen + mFOLFIRINOX in Advanced/Metastatic Pancreatic Cancer
NCT06079346Phase 3Recruiting
- Sponsor
- Oncotelic Therapeutics, Inc.
- Start
- May 2024
- Primary completion
- Jun 2026
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 3 trial of trabedersen in pancreatic ductal adenocarcinoma (PDAC), sponsored by Oncotelic Therapeutics, Inc.. Started May 2024; status: recruiting.
02
Drugs
trabedersen
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06079346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06079346.